|
|
 | | | |
- close
- close
- close
- close
QUOTE AND NEWS
PR Newswire
May 14
Comment
MOUNTAIN VIEW, Calif., May 14, 2012 /PRNewswire/ -- Fenwick & West, a leading technology and life sciences law firm, is pleased to announce that Effie Toshav has joined the firm as a partner in its Life Sciences Group. Ms. Toshav's national practice
StreetInsider.com
May 10
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/AVI+BioPharma%2C+Inc.+%28AVII%29+Misses+Q1+EPS+by+6c/7427027.html for the full story.
Marketwire
May 10
Comment
BOTHELL, WA -- (Marketwire) -- 05/10/12 -- AVI BioPharma, Inc. (NASDAQ: AVII) Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs Continue to Advance in Clinical Development Strong Dataset Presented on AVI's Lead Drug Candidate
Marketwire
May 4
Comment
NEW YORK, NY -- (Marketwire) -- 05/04/12 -- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will
Marketwire
May 3
Comment
BOTHELL, WA -- (Marketwire) -- 05/03/12 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, will report first quarter 2012 financial results after the NASDAQ Global Market closes on Thursday, May 10, 2012. Subsequently, at
Marketwire
Apr 25
Comment
BOTHELL, WA -- (Marketwire) -- 04/25/12 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced that data from a Phase IIb study evaluating eteplirsen as a treatment for boys with Duchenne muscular dystrophy (DMD) will
StreetInsider.com
Apr 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/AVI+Biopharma+%28AVII%29+Chief+Scientific+Officer+to+Resign/7341910.html for the full story.
MarketWatch
Apr 2
Comment
AVI BioPharma Inc. shares tumbled early Monday after the biotech group released mixed results from a Phase II study for its drug candidate eteplirsen in the treatment of Duchenne muscular dystrophy in boys. Shares of AVI were down 24% to $1.17 in...
TheStreet.com
Apr 2
Comment
BOTHELL, Wash. (TheStreet) -- A novel "genetic fix" developed by AVI Biopharma was able to increase levels of a key protein involved with muscle function in patients with muscular dystrophy, according to results from a small study announced...
Marketwire
Apr 2
Comment
BOTHELL, WA -- (Marketwire) -- 04/02/12 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
